The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > BUSINESS
BUSINESS
- Santen Obtains Approval for Preservative-Free Ophthalmic Solution Tapros
January 22, 2013
- Kyorin and Daiichi Sankyo to Cancel Agreement on Uritos in Brazil
January 22, 2013
- Pfizer Detailing Infectious Disease Portfolios across Divisions
January 21, 2013
- Tokyo District Court to Issue Ruling on Actos Patent Suit on Feb. 27 after Takeda Lost Legal Battle in Osaka
January 21, 2013
- Drug Makers’ Specialty Care Pipelines Hit Snags in Late-Stage Development
January 21, 2013
- Daiichi Sankyo to Integrate Business Operations in Thailand with Ranbaxy
January 21, 2013
- Japan Could Get Left Behind in New Age of Open Innovation: Dr Fujimoto of Eli Lilly Japan
January 21, 2013
- Maruho to License Infantile Hemangioma Treatment from French Company
January 18, 2013
- Teijin Pharma Launches Acromegaly Treatment Somatuline
January 18, 2013
- Celgene K.K. Focused on MR Training Aiming for No. 1 Ranking Among Hematologists in 2013
January 18, 2013
- Ethical Drug Sales Up 2.4% in November: Crecon Report
January 18, 2013
- OrphanPacific’s Orphan Drug Biz Faces Rough Going with Rising Costs
January 17, 2013
- AZ K.K. President Hudson to Leave, Operations in Japan under Control of UK CFO
January 17, 2013
- Domestic Drug Makers Working to Escape Dependence on Long-Listed Drugs through New Product Development
January 17, 2013
- Tivantinib Fails to Meet Primary Endpoint in PII Trial for Colorectal Cancer: Daiichi Sankyo
January 17, 2013
- Epadel Fails to Meet Endpoint in PII Trial with NASH Patients
January 16, 2013
- Eisai's Farletuzumab Fails to Meet Primary Endpoint in PIII Trial
January 16, 2013
- Otsuka Files for Approval for New Dry Powder Inhaler of Meptin
January 16, 2013
- GMP Violations at Drug Substance Makers Prompt Series of New Voluntary Recalls of Generics; Stable Supplies Disrupted
January 16, 2013
- Astellas and Sanwa Kagaku Launch Hyperkalemia Treatment Argamate Granule
January 15, 2013
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…